Phenotyping [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2006-02-28 14:54 (6422 d 13:04 ago) – Posting: # 78
Views: 9,246

Dear Essar,

different Genotypes (coded in the individual Genome) express different forms (polymorphism) of proteins e.g., metabolizing liver enzymes (CYP450) and transporters (PGP). Individuals showing different forms are called Phenotypes.
For some drugs being metabolized we see different genotypes in the population (e.g., fast/extensive [aka EM] and slow/poor metabolizers [aka PM]).

In the general BE-setting this is of no interest, since the phenotype does not change (a poor metabolizer shows high concentrations both for test and reference, and a fast metabolizer low conc's...)

If your drug shows such a pattern (generally you notice it by a large inter-individual CV and ratio of >10 of the highest/lowest AUCs), two points are of interest:
If you plan a cross-over multiple dose study for such a drug, you may consider phenotyping in screening for safety reasons (i.e., include only FMs; otherwise you will end up in toxic range for the PMs). Example: paroxetine.
If you plan a parallel study, phenotyping is almost mandatory. Imagine a situation where you have by chance 5% slow metabolizers in one group, and 10% in the other; you results will be useless (the difference in concentrations will reflect the phenotypes, and not a difference in formulations). In such a case both groups should consist of an equal number of fast/slow metabolizers.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,627 registered users;
20 visitors (0 registered, 20 guests [including 8 identified bots]).
Forum time: 04:59 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz